glp-1 for autoimmune Agonists in Disease Health Feed - Glp-1 Drugs

Eli Lilly says full data from its latest Phase 3 trial will be published in a peer-reviewed journal at a future date.

doi:10.1053/j.gastro.2025.06.003 13

What You Need to Know About Orforglipron t2diabetesnetwork Apr 1 4 min read Updated: May 19 Written by Clare Koning, RN, PhD T2D Network | April 2026 | 6 min read Key Highlights Orforglipron is a once-daily GLP-1 pill: no injections, no food or water timing restrictions Phase 3 trials showed A1C reductions of 1.3%1.6% and meaningful weight loss In a head-to-head trial published in The Lancet , it outperformed oral semaglutide on every key endpoint Regulatory submissions are underway in 40+ countries: U.S

10.1002/cne.22126 [DOI] [PubMed] [Google Scholar] Sisley, S

"I was a tiny bit overweightthey were like, 'You're prediabetic

But theres something no one warned you about during your weight loss journey: what happens to your skin when the fat disappears